Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNV1521 and daraxonrasib in Advanced Pancreatic Cancer
NCT07756281Phase 1Recruiting
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNV1521 in pancreatic cancer (PC) and acinar cell carcinoma of the pancreas (ACC). Primary endpoint: Safety and tolerability of SNV1521 plus daraxonrasib (TEAEs, SAEs, DLTs) at 1 year. Started Sep 2026; status: recruiting.
02
Drugs
SNV1521
03
Conditions
pancreatic cancer (PC)acinar cell carcinoma of the pancreas (ACC)
Beyond the preview
Go deeper on NCT07756281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756281.